铁死亡在肝纤维化进展和治疗中的作用

李俊钢; 李丰帆; 刘珍妮; 曾唯楚; 张伟林; 刘佩婷; 李炳杵; 吕星; 陈若虹; 陈芷阳; 胡敏

doi:10.12449/JCH260628

铁死亡在肝纤维化进展和治疗中的作用

DOI: 10.12449/JCH260628

中南大学湘雅二医院检验医学科，湖南省临床分子诊断中心，分子诊断技术湖南省工程研究中心，湖南省感染性疾病分子诊断临床医学研究中心，长沙 410011

基金项目:

国家自然科学基金 (82270658);

中南大学研究生创新项目 (2024XQLH103)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：李俊钢、胡敏负责设计综述框架，起草综述；李俊钢负责绘制图表；吕星、李丰帆、刘珍妮、曾唯楚、张伟林、刘佩婷、李炳杵、陈若虹、陈芷阳负责综述修改；胡敏负责拟定综述思路，指导撰写文章并最后定稿。

详细信息

通信作者:
胡敏， huminjyk@csu.edu.cn （ORCID： 0000-0001-7886-8174）

计量
- 文章访问数: 6
- HTML全文浏览量: 2
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2025-08-13
- 录用日期: 2025-09-30
- 出版日期: 2026-06-25

Role of ferroptosis in the progression and treatment of liver fibrosis

Department of Laboratory Medicine，The Second Xiangya Hospital of Central South University；Hunan Provincial Center for Clinical Molecular Diagnostics；Hunan Engineering Research Center for Molecular Diagnostic Technology；Hunan Clinical Research Center for Molecular Diagnosis of Infectious Diseases，Changsha 410011，China

Research funding:

National Natural Science Foundation of China (82270658);

Central South University Graduate Innovation Project (2024XQLH103)

More Information

Corresponding author: HU Min， huminjyk@csu.edu.cn （ORCID： 0000-0001-7886-8174）

摘要

摘要: 肝纤维化是慢性肝病进展中的关键病理过程，主要由肝星状细胞活化驱动，其特征为细胞外基质的过度沉积。程序性细胞死亡在肝纤维化中普遍存在，其在不同细胞中的作用多样，既是细胞通过新陈代谢维持稳态的方式，也可调控疾病的发生与发展。其中，铁死亡因与脂代谢的密切关联成为近年的研究热点。本文系统阐述了脂代谢、铁死亡和肝纤维化的相关概念，深入分析了铁死亡在脂代谢和肝纤维化中扮演的桥梁作用与双重调控角色，进而指出靶向肝星状细胞铁死亡在肝纤维化治疗中具有临床应用价值，为肝纤维化的机制研究和临床干预策略的优化提供了新视角。
- 肝纤维化 /
- 铁死亡 /
- 治疗学
Abstract: Liver fibrosis is a critical pathological process in the progression of chronic liver diseases and is mainly driven by the activation of hepatic stellate cells， and it is characterized by excessive deposition of extracellular matrix. Programmed cell death is widely observed in liver fibrosis and plays diverse roles in different types of cells. It is not only a mechanism for maintaining cellular homeostasis through metabolism， but it can also regulate the development and progression of diseases. Ferroptosis has recently emerged as a research focus due to its close association with lipid metabolism. This article systematically reviews the related concepts of lipid metabolism， ferroptosis， and liver fibrosis， analyzes the bridging role and dual regulatory function of ferroptosis in lipid metabolism and liver fibrosis， and further highlights the clinical application value of targeting ferroptosis in hepatic stellate cells for the treatment of liver fibrosis， in order to provide new perspectives for the mechanistic studies on liver fibrosis and the optimization of related clinical intervention strategies.
- Hepatic Fibrosis /
- Ferroptosis /
- Therapeutics

HTML全文

注： SLC39A14，溶质载体家族39成员14；FGF21，成纤维细胞生长因子21；HO-1，血红素加氧酶1；ROS，活性氧；ferrostatin-1，铁抑素-1；m⁶A，N6-甲基腺苷；ELAVL1，胚胎致死性异常视觉样蛋白1；NCOA4，核受体辅激活蛋白4；ZFP36，锌指蛋白36；BECN1，Beclin1蛋白；SLC25A37，溶质载体家族25成员37；ATG16L1，自噬相关16样蛋白1；HSC，肝星状细胞。

图 1 铁死亡在肝纤维化中的双重作用

Figure 1. The dual role of ferroptosis in liver fibrosis

下载: 全尺寸图片幻灯片

参考文献(54)

[1]	LU JL, YU CX, SONG LJ. Programmed cell death in hepatic fibrosis: Current and perspectives[J]. Cell Death Discov, 2023, 9( 1): 449. DOI: 10.1038/s41420-023-01749-8.
[2]	BATALLER R, BRENNER DA. Liver fibrosis[J]. J Clin Invest, 2005, 115( 2): 209- 218. DOI: 10.1172/jci24282.
[3]	NEWTON K, STRASSER A, KAYAGAKI N, et al. Cell death[J]. Cell, 2024, 187( 2): 235- 256. DOI: 10.1016/j.cell.2023.11.044.
[4]	CALIGIURI A, GENTILINI A, PASTORE M, et al. Cellular and molecular mechanisms underlying liver fibrosis regression[J]. Cells, 2021, 10( 10): 2759. DOI: 10.3390/cells10102759.
[5]	GAO RY, TANG HY, MAO JW. Programmed cell death in liver fibrosis[J]. J Inflamm Res, 2023, 16: 3897- 3910. DOI: 10.2147/JIR.S427868.
[6]	DIXON SJ, LEMBERG KM, LAMPRECHT MR, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death[J]. Cell, 2012, 149( 5): 1060- 1072. DOI: 10.1016/j.cell.2012.03.042.
[7]	SU LJ, ZHANG JH, GOMEZ H, et al. Reactive oxygen species-induced lipid peroxidation in apoptosis, autophagy, and ferroptosis[J]. Oxid Med Cell Longev, 2019, 2019: 5080843. DOI: 10.1155/2019/5080843.
[8]	LIANG DG, MINIKES AM, JIANG XJ. Ferroptosis at the intersection of lipid metabolism and cellular signaling[J]. Mol Cell, 2022, 82( 12): 2215- 2227. DOI: 10.1016/j.molcel.2022.03.022.
[9]	DUKEWICH M, YUAN LY, TERRAULT NA. At the crossroads of health and disease: Consequences of fat in the liver[J]. Annu Rev Physiol, 2025, 87( 1): 325- 352. DOI: 10.1146/annurev-physiol-022724-105515.
[10]	SHIMANO H, SATO R. SREBP-regulated lipid metabolism: Convergent physiology: Divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13( 12): 710- 730. DOI: 10.1038/nrendo.2017.91.
[11]	WANG B, TONTONOZ P. Liver X receptors in lipid signalling and membrane homeostasis[J]. Nat Rev Endocrinol, 2018, 14( 8): 452- 463. DOI: 10.1038/s41574-018-0037-x.
[12]	MONROY-RAMIREZ HC, GALICIA-MORENO M, SANDOVAL-RODRIGUEZ A, et al. PPARs as metabolic sensors and therapeutic targets in liver diseases[J]. Int J Mol Sci, 2021, 22( 15): 8298. DOI: 10.3390/ijms22158298.
[13]	JIANG LY, ZHANG HJ, XIAO DS, et al. Farnesoid X receptor(FXR): Structures and ligands[J]. Comput Struct Biotechnol J, 2021, 19: 2148- 2159. DOI: 10.1016/j.csbj.2021.04.029.
[14]	JIANG XJ, STOCKWELL BR, CONRAD M. Ferroptosis: Mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22( 4): 266- 282. DOI: 10.1038/s41580-020-00324-8.
[15]	LI FJ, LONG HZ, ZHOU ZW, et al. System Xc ^-/GSH/GPX4 axis: An important antioxidant system for the ferroptosis in drug-resistant solid tumor therapy[J]. Front Pharmacol, 2022, 13: 910292. DOI: 10.3389/fphar.2022.910292.
[16]	BERSUKER K, HENDRICKS JM, LI ZP, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J]. Nature, 2019, 575( 7784): 688- 692. DOI: 10.1038/s41586-019-1705-2.
[17]	LIU J, KUANG FM, KROEMER G, et al. Autophagy-dependent ferroptosis: Machinery and regulation[J]. Cell Chem Biol, 2020, 27( 4): 420- 435. DOI: 10.1016/j.chembiol.2020.02.005.
[18]	XU CF, LIU ZL, XIAO JW. Ferroptosis: A double-edged sword in gastrointestinal disease[J]. Int J Mol Sci, 2021, 22( 22): 12403. DOI: 10.3390/ijms222212403.
[19]	DING KY, LIU CB, LI L, et al. Acyl-CoA synthase ACSL4: An essential target in ferroptosis and fatty acid metabolism[J]. Chin Med J, 2023, 136( 21): 2521- 2537. DOI: 10.1097/CM9.0000000000002533.
[20]	DOLL S, PRONETH B, TYURINA YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition[J]. Nat Chem Biol, 2017, 13( 1): 91- 98. DOI: 10.1038/nchembio.2239.
[21]	THOMAS C, JALIL A, MAGNANI C, et al. LPCAT3 deficiency in hematopoietic cells alters cholesterol and phospholipid homeostasis and promotes atherosclerosis[J]. Atherosclerosis, 2018, 275: 409- 418. DOI: 10.1016/j.atherosclerosis.2018.05.023.
[22]	YANG WS, KIM KJ, GASCHLER MM, et al. Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis[J]. Proc Natl Acad Sci USA, 2016, 113( 34): E4966- E4975. DOI: 10.1073/pnas.1603244113.
[23]	POPE LE, DIXON SJ. Regulation of ferroptosis by lipid metabolism[J]. Trends Cell Biol, 2023, 33( 12): 1077- 1087. DOI: 10.1016/j.tcb.2023.05.003.
[24]	SUN DY, WANG LF, WU YF, et al. Lipid metabolism in ferroptosis: Mechanistic insights and therapeutic potential[J]. Front Immunol, 2025, 16: 1545339. DOI: 10.3389/fimmu.2025.1545339.
[25]	GENG F, GUO DL. SREBF1/SREBP-1 concurrently regulates lipid synthesis and lipophagy to maintain lipid homeostasis and tumor growth[J]. Autophagy, 2024, 20( 5): 1183- 1185. DOI: 10.1080/15548627.2023.2275501.
[26]	BAI YS, MENG LJ, HAN L, et al. Lipid storage and lipophagy regulates ferroptosis[J]. Biochem Biophys Res Commun, 2019, 508( 4): 997- 1003. DOI: 10.1016/j.bbrc.2018.12.039.
[27]	MAGTANONG L, KO PJ, TO M, et al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state[J]. Cell Chem Biol, 2019, 26( 3): 420- 432.e9. DOI: 10.1016/j.chembiol.2018.11.016.
[28]	YI JM, ZHU JJ, WU J, et al. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis[J]. Proc Natl Acad Sci USA, 2020, 117( 49): 31189- 31197. DOI: 10.1073/pnas.2017152117.
[29]	SUN Q, LIU DM, CUI WW, et al. Cholesterol mediated ferroptosis suppression reveals essential roles of Coenzyme Q and squalene[J]. Commun Biol, 2023, 6( 1): 1108. DOI: 10.1038/s42003-023-05477-8.
[30]	WU AM, FENG B, YU J, et al. Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis[J]. Redox Biol, 2021, 46: 102131. DOI: 10.1016/j.redox.2021.102131.
[31]	GAUTHERON J, GORES GJ, RODRIGUES CMP. Lytic cell death in metabolic liver disease[J]. J Hepatol, 2020, 73( 2): 394- 408. DOI: 10.1016/j.jhep.2020.04.001.
[32]	YU YY, JIANG L, WANG H, et al. Hepatic transferrin plays a role in systemic iron homeostasis and liver ferroptosis[J]. Blood, 2020, 136( 6): 726- 739. DOI: 10.1182/blood.2019002907.
[33]	ZHANG ZL, GUO M, LI YJ, et al. RNA-binding protein ZFP36/TTP protects against ferroptosis by regulating autophagy signaling pathway in hepatic stellate cells[J]. Autophagy, 2020, 16( 8): 1482- 1505. DOI: 10.1080/15548627.2019.1687985.
[34]	ZHANG ZL, YAO Z, WANG L, et al. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells[J]. Autophagy, 2018, 14( 12): 2083- 2103. DOI: 10.1080/15548627.2018.1503146.
[35]	SHEN M, LI YJ, WANG YQ, et al. N⁶-methyladenosine modification regulates ferroptosis through autophagy signaling pathway in hepatic stellate cells[J]. Redox Biol, 2021, 47: 102151. DOI: 10.1016/j.redox.2021.102151.
[36]	GUO M, ZHUANG YS, WU Y, et al. The cell fate regulator DACH1 modulates ferroptosis through affecting P53/SLC25A37 signaling in fibrotic disease[J]. Hepatol Commun, 2024, 8( 3): e0396. DOI: 10.1097/HC9.0000000000000396.
[37]	CHO SS, YANG JH, LEE JH, et al. Ferroptosis contribute to hepatic stellate cell activation and liver fibrogenesis[J]. Free Radic Biol Med, 2022, 193( Pt 2): 620- 637. DOI: 10.1016/j.freeradbiomed.2022.11.011.
[38]	WANG Z, DU KL, JIN NK, et al. Macrophage in liver fibrosis: Identities and mechanisms[J]. Int Immunopharmacol, 2023, 120: 110357. DOI: 10.1016/j.intimp.2023.110357.
[39]	YANG Y, WANG Y, GUO L, et al. Interaction between macrophages and ferroptosis[J]. Cell Death Dis, 2022, 13( 4): 355. DOI: 10.1038/s41419-022-04775-z.
[40]	YUAN SY, WEI C, LIU GF, et al. Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1α/SLC7A11 pathway[J]. Cell Prolif, 2022, 55( 1): e13158. DOI: 10.1111/cpr.13158.
[41]	ZENG FT, NIJIATI S, TANG LG, et al. Ferroptosis detection: From approaches to applications[J]. Angew Chem Int Ed, 2023, 62( 35): e202300379. DOI: 10.1002/anie.202300379.
[42]	KITSUGI K, NORITAKE H, MATSUMOTO M, et al. Simvastatin inhibits hepatic stellate cells activation by regulating the ferroptosis signaling pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869( 7): 166750. DOI: 10.1016/j.bbadis.2023.166750.
[43]	LIN LF, LI XM, LI YF, et al. Ginsenoside Rb1 induces hepatic stellate cell ferroptosis to alleviate liver fibrosis via the BECN1/SLC7A11 axis[J]. J Pharm Anal, 2024, 14( 5): 100902. DOI: 10.1016/j.jpha.2023.11.009.
[44]	KONG ZY, LIU R, CHENG YR. Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway[J]. Biomed Pharmacother, 2019, 109: 2043- 2053. DOI: 10.1016/j.biopha.2018.11.030.
[45]	YU T, LU XJ, LIANG Y, et al. Naringenin alleviates liver fibrosis by triggering autophagy-dependent ferroptosis in hepatic stellate cells[J]. Heliyon, 2024, 10( 7): e28865. DOI: 10.1016/j.heliyon.2024.e28865.
[46]	YI JZ, WU SY, TAN SW, et al. Berberine alleviates liver fibrosis through inducing ferrous redox to activate ROS-mediated hepatic stellate cells ferroptosis[J]. Cell Death Discov, 2021, 7( 1): 374. DOI: 10.1038/s41420-021-00768-7.
[47]	LIU LK, DU JH, FAN HQ, et al. Blueberry anthocyanins improve liver fibrosis by regulating NCOA4 ubiquitination through TRIM7 to affect ferroptosis of hepatic stellate cells[J]. Am J Physiol Gastrointest Liver Physiol, 2024, 326( 4): G426- G437. DOI: 10.1152/ajpgi.00227.2023.
[48]	TUOHETAHUNTILA M, SPEE B, KRUITWAGEN HS, et al. Role of long-chain acyl-CoA synthetase 4 in formation of polyunsaturated lipid species in hepatic stellate cells[J]. Biochim Biophys Acta, 2015, 1851( 2): 220- 230. DOI: 10.1016/j.bbalip.2014.12.003.
[49]	SHIMOMURA I, SHIMANO H, HORTON JD, et al. Differential expression of exons 1a and 1c in mRNAs for sterol regulatory element binding protein-1 in human and mouse organs and cultured cells[J]. J Clin Invest, 1997, 99( 5): 838- 845. DOI: 10.1172/JCI119247.
[50]	LEE EH, LEE JH, KIM DY, et al. Loss of SREBP-1c ameliorates iron-induced liver fibrosis by decreasing lipocalin-2[J]. Exp Mol Med, 2024, 56( 4): 1001- 1012. DOI: 10.1038/s12276-024-01213-2.
[51]	GENG F, ZHONG YG, SU HL, et al. SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells[J]. Cell Rep, 2023, 42( 7): 112790. DOI: 10.1016/j.celrep.2023.112790.
[52]	DODSON M, CASTRO-PORTUGUEZ R, ZHANG DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis[J]. Redox Biol, 2019, 23: 101107. DOI: 10.1016/j.redox.2019.101107.
[53]	SUN XF, OU ZH, CHEN RC, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells[J]. Hepatology, 2016, 63( 1): 173- 184. DOI: 10.1002/hep.28251.
[54]	MINAMI JK, MORROW D, BAYLEY NA, et al. CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis[J]. Cancer Cell, 2023, 41( 6): 1048- 1060.e9. DOI: 10.1016/j.ccell.2023.05.001.